ZYDUS SEEKS NOD FOR HUMAN CLINICAL TRIALS

NEW DELHI: Pharmaceutical major Zydus Cadila has sought the drugs controller’s permission to initiate phase 1/3 human clinical trials for its monoclonal antibodies to treat Covid-19, the company said on Thursday.

It is the only Indian company to have developed a neutralising monoclonal antibody-based cocktail for the treatment of Covid. “At this juncture, there is a critical need to explore safer and more efficacious treatments to combat Covid. It is important to look at different stages of the disease progression and look at options that can reduce a patient’s suffering and discomfort. We believe that ZRC-3308 has the potential to address these concerns and provide safe treatment,” said Sharvil Patel, managing director, Cadila Healthcare Ltd.